Javascript must be enabled to continue!
Selecting and collecting outcomes for clinical trials: an international qualitative study exploring stakeholder perspectives
View through CrossRef
Abstract
Introduction
Selecting and collecting data to support appropriate primary and secondary outcomes is a critical step in designing trials that can change clinical practice. In this study, we aimed to investigate who contributes to the process of selecting and collecting trial outcomes, and how these people are involved. This work serves two main purposes: 1) it provides the trials community with evidence to demonstrate how outcomes are currently selected and collected, and 2) it allows people involved in trial design and conduct to pick apart these processes to consider how efficiencies and improvements can be made.
Methods
One-with-one semi-structured interviews, supported by a topic guide to ensure coverage of key content. The Framework approach was used for thematic analysis of data, and themes were linked through constant comparison of data both within and across stakeholder groups.
Participants were twenty-nine international trialists from various stakeholder groups, working primarily on designing and/or delivering phase III pragmatic effectiveness trials. Their experience spanned various funders, trial settings, clinical specialties, intervention types, and participant populations.
Results
We identified three descriptive themes encompassing the process of primary and secondary outcome selection, primary and secondary outcome collection, and the publication of outcome data. Within these themes, participants raised issues around the following:
1) Outcome selection: clarity of the research question; confidence in selecting trial outcomes and how confidence decreases with increased experience; interplay between different stakeholders; how patients and the public are involved in outcome selection; perceived impact of poor outcome selection including poor recruitment and/or retention; and use of core outcome sets.
2) Outcome collection: disconnect between decisions made by outcome selectors and the practical work done by outcome collectors; potential impact of outcome measures on trial participants; potential impact on trial staff workload; and use of routinely collected data.
3) Publication of outcome data: difficulties in finding time to write and revise manuscripts for publication due to time and funding constraints.
Participants overwhelmingly focused on the process of outcome selection, a topic they talked about unprompted. When prompted, participants do discuss outcome collection, but poor communication between selectors and collectors at the trial design stage means that outcome selection is rarely linked with the data collection workload it generates.
Discussion
Stakeholders involved in the design and conduct of trials fail to connect decisions around outcome selection with data collection workload. Publication of outcome data and effective dissemination of trial results are hindered due to the project-based culture of some academic research.
Research Square Platform LLC
Title: Selecting and collecting outcomes for clinical trials: an international qualitative study exploring stakeholder perspectives
Description:
Abstract
Introduction
Selecting and collecting data to support appropriate primary and secondary outcomes is a critical step in designing trials that can change clinical practice.
In this study, we aimed to investigate who contributes to the process of selecting and collecting trial outcomes, and how these people are involved.
This work serves two main purposes: 1) it provides the trials community with evidence to demonstrate how outcomes are currently selected and collected, and 2) it allows people involved in trial design and conduct to pick apart these processes to consider how efficiencies and improvements can be made.
Methods
One-with-one semi-structured interviews, supported by a topic guide to ensure coverage of key content.
The Framework approach was used for thematic analysis of data, and themes were linked through constant comparison of data both within and across stakeholder groups.
Participants were twenty-nine international trialists from various stakeholder groups, working primarily on designing and/or delivering phase III pragmatic effectiveness trials.
Their experience spanned various funders, trial settings, clinical specialties, intervention types, and participant populations.
Results
We identified three descriptive themes encompassing the process of primary and secondary outcome selection, primary and secondary outcome collection, and the publication of outcome data.
Within these themes, participants raised issues around the following:
1) Outcome selection: clarity of the research question; confidence in selecting trial outcomes and how confidence decreases with increased experience; interplay between different stakeholders; how patients and the public are involved in outcome selection; perceived impact of poor outcome selection including poor recruitment and/or retention; and use of core outcome sets.
2) Outcome collection: disconnect between decisions made by outcome selectors and the practical work done by outcome collectors; potential impact of outcome measures on trial participants; potential impact on trial staff workload; and use of routinely collected data.
3) Publication of outcome data: difficulties in finding time to write and revise manuscripts for publication due to time and funding constraints.
Participants overwhelmingly focused on the process of outcome selection, a topic they talked about unprompted.
When prompted, participants do discuss outcome collection, but poor communication between selectors and collectors at the trial design stage means that outcome selection is rarely linked with the data collection workload it generates.
Discussion
Stakeholders involved in the design and conduct of trials fail to connect decisions around outcome selection with data collection workload.
Publication of outcome data and effective dissemination of trial results are hindered due to the project-based culture of some academic research.
Related Results
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
ABSTRACT
Background
Research infra-structure is essential for conducting phase III cancer clinical trials as its lack precludes...
1349. Lesson Learned from Investigators of Clinical Trials to Identify Therapeutics for COVID-19: Qualitative Study
1349. Lesson Learned from Investigators of Clinical Trials to Identify Therapeutics for COVID-19: Qualitative Study
Abstract
Background
Implementation of high-quality clinical trials especially early in the pandemic caused burden on clinical in...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
STAKEHOLDER ENGAGEMENT AND PROJECT PERFORMANCE OF ROAD INFRASTRUCTURE PROJECTS IN CENTRAL EQUATORIA STATE, SOUTH SUDAN
STAKEHOLDER ENGAGEMENT AND PROJECT PERFORMANCE OF ROAD INFRASTRUCTURE PROJECTS IN CENTRAL EQUATORIA STATE, SOUTH SUDAN
Objective: This study sought to establish the relationship between stakeholder engagement practices and the performance of road infrastructure projects in Central Equatoria State, ...
4552 Pediatrician Readiness to Participate in Clinical Trials: Roles of interest, barriers and interventions
4552 Pediatrician Readiness to Participate in Clinical Trials: Roles of interest, barriers and interventions
OBJECTIVES/GOALS: Clinical trials are the gold standard for developing evidence-based medicine. However, 20% of pediatric randomized clinical trials are discontinued and about 30% ...
Collecting Innovation: Innovative Collecting, curated by Bethany Turner-Pemberton, Special Collections Museum, Manchester Metropolitan University, 14 November 2023–29 February 2024
Collecting Innovation: Innovative Collecting, curated by Bethany Turner-Pemberton, Special Collections Museum, Manchester Metropolitan University, 14 November 2023–29 February 2024
Collecting Innovation: Innovative Collecting was a temporary exhibition at the Special Collections Museum, Manchester Metropolitan University, from 14 November 2023 to 29 February ...
Workforce, economic, and infrastructural barriers to global oncology clinical trial participation: Focus on sub-Saharan Africa.
Workforce, economic, and infrastructural barriers to global oncology clinical trial participation: Focus on sub-Saharan Africa.
11091
Background:
Despite Sub-Saharan Africa's (SSA) growing cancer burden, the region remains grossly underrepresented in global onco...

